Peer Exchange


Advances in Early Treatment Approaches in Multiple Sclerosis

Fred D. Lublin, MD leads a discussion on the 2017 revisions to the McDonald criteria to diagnose multiple sclerosis.

Key opinion leaders discuss red flags in making a multiple sclerosis diagnosis and the possibility for misdiagnosis.

Expert neurologists outline how the use of MRI has changed the diagnosis of multiple sclerosis and the importance of standardized protocols.

Fred D. Lublin, MD, outlines the 4 clinical courses in multiple sclerosis and that they must be framed in time.

The decrease of the modern conversion rate to secondary progressive disease is discussed as well as the importance of a wellness program.

Panelists discuss the importance and value of early identification and treatment of multiple sclerosis.

Key opinion leaders agree there is no consensus on choosing initial therapy for treatment of multiple sclerosis.

Panelists agree there is no treatment algorithm when starting therapy for multiple sclerosis but discuss some factors to consider when choosing therapy.

Implications for using cladribine or diroximel fumarate as therapy for relapsing multiple sclerosis, as well as considerations for selecting an appropriate dose of fingolimod.

Stephen C. Krieger, MD, outlines the ASSESS clinical trial of the orally administered S1P receptor modulator fingolimod.

 Progress in the treatment of patients with multiple sclerosis.

A discussion of the EXPAND phase III clinical trial of the selective S1P receptor modulator siponimod for treatment of multiple sclerosis.

Panelists debate the use of alemtuzumab in multiple sclerosis, weighing the high efficacy vs the high frequency of autoimmune complications and serious adverse events.

The panel outlines data from the phase 3 ORACLE MS and CLARITY extension trials of cladribine and the phase 3 EVOLVE-MS-2 trial of these 2 drugs recently FDA approved for multiple sclerosis. 

Key opinion leaders discuss the use of natalizumab for multiple sclerosis and the JCV antibody blood test to determine risk of developing PML.

Expert neurologists offer opinions on some of the original drugs to treat multiple sclerosis, including interferon and glatiramer acetate.

A discussion of some drugs in development for multiple sclerosis, including the ASCLEPIOS I and II phase 3 trials of ofatumumab.

Panelists wrap up their discussion on multiple sclerosis by identifying areas of unmet needs and offering advice to community-based neurologists.
SAP Partner Banner